ENZC (Enzolytics) LT-Debt-to-Total-Asset: 0.21 (As of Jun. 2011)


What is Enzolytics LT-Debt-to-Total-Asset?

Enzolytics ENZC -10.00% LT-Debt-to-Total-Asset is 0.21 as of Jun. 2011.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Enzolytics's long-term debt to total assests ratio for the quarter that ended in Jun. 2011 was 0.21.

Enzolytics's long-term debt to total assets ratio declined from Jun. 2010 (0.23) to Jun. 2011 (0.21). It may suggest that Enzolytics is progressively becoming less dependent on debt to grow their business.

Enzolytics  (OTCPK:ENZC) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Enzolytics LT-Debt-to-Total-Asset Related Terms

Enzolytics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Enzolytics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzolytics LT-Debt-to-Total-Asset Chart

Enzolytics Annual Data
Trend Dec07 Jul08 Dec09 Dec10
LT-Debt-to-Total-Asset
2.05 0.00 1.62 0.31

Enzolytics Quarterly Data
Sep07 Dec07 Apr08 Jul08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.21 0.31 0.18 0.21

Enzolytics LT-Debt-to-Total-Asset Calculation

Enzolytics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2010 is calculated as

LT Debt to Total Assets (A: Dec. 2010 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2010 )/Total Assets (A: Dec. 2010 )
=0.048/0.153
=0.31

Enzolytics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2011 is calculated as

LT Debt to Total Assets (Q: Jun. 2011 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2011 )/Total Assets (Q: Jun. 2011 )
=0.024/0.112
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.21 mean?
Enzolytics (ENZC) has a LT-Debt-to-Total-Asset of 0.21 as of Jun. 2011. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Enzolytics and its competitors.
Is Enzolytics' LT-Debt-to-Total-Asset too high?
Enzolytics' current LT-Debt-to-Total-Asset is 0.21.
How does Enzolytics' LT-Debt-to-Total-Asset compare to competitors?
Enzolytics' LT-Debt-to-Total-Asset of 0.21 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Enzolytics and its competitors. Enzolytics's current LT-Debt-to-Total-Asset is 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzolytics stock overvalued right now?
Enzolytics (ENZC) has a current LT-Debt-to-Total-Asset of 0.21. The current LT-Debt-to-Total-Asset is 0.21. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Enzolytics (ENZC), the current LT-Debt-to-Total-Asset is 0.21 as of Jun. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enzolytics Business Description

Address 1101 Raintree Circle, Suite 130, Allen, TX, USA, 75013
Enzolytics Inc is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The company is committed to creating drugs for the good health of mankind. ENZC's flagship compound, ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use.